Jonathan Schur is a partner in Goodwin’s Life Sciences group. Mr. Schur advises pharmaceutical and medical device companies in structuring collaborations, mergers, acquisitions and divestitures, and advancing products from discovery until commercialization. He has significant experience in cross-border transactions and is known for his ability to bring parties of transactions together, effectively bridging legal and cultural differences, in particular between European and U.S. companies. He also works with clients to arrange venture and later-stage financing, as well as representing them pre-IPO and at the IPO stage.

Mr. Schur counsels companies with activities that cross the Atlantic or Pacific on legal and management issues that need to be addressed to ensure efficient operations and achieve regulatory compliance. This includes the regulatory aspects of product and pricing authorizations, clinical trials, agreements with hospitals and physicians, privacy and marketing practices in the life sciences sector.

Listed in Chambers Europe 2012 for Pharma-Life Sciences Corporate in France, “dual U.S. and French qualified Jonathan Schur has a strong corporate and regulatory background. He regularly advises pharma and medical device clients on M&A and joint ventures.” In addition, Mr. Schur is listed by The Legal 500 (U.S.) for life sciences, where he is cited as being “highly skilled and committed.” He is also recommended by Practical Law Company’s “Which Lawyer?” guide for both regulatory and corporate matters.

Prior to joining Goodwin in 2018, Mr. Schur was a partner and former co-managing partner of the Paris office at Dechert LLP. He is fluent in French and English.





Significant representations include:

  • Onxeo in connection with the sale to Acrotech Biopharma of the ex-North America rights to belinostat
  • Bicycle Therapeutics’ collaborations with AstraZeneca,* Sanofi, and Cancer Research UK
  • Bicycle Therapeutics’ initial public offering on the NASDAQ Global Select Market
  • Zealand Pharma in connection with its collaborations with Sanofi* and Boehringer-Ingelheim* and its initial public offerings on NASDAQ Copenhagen and the NASDAQ Global Select Market
  • Remedy Pharmaceuticals in connection with the sale of CIRARA™ (intravenous glyburide) to Biogen*
  • Gadeta in connection with its strategic collaboration and purchase option with Kite, a Gilead company
  • Enterome in connection with its global licensing, co-development and co-promotion agreement with Takeda
  • ExScientia in connection with its AI drug discovery collaboration with Celgene
  • Onxeo in connection with its monetization of royalties for BELEODAQ®
  • Prexton Therapeutics in connection with its structured sale to Lundbeck
  • AM-Pharma in connection with Pfizer’s acquisition of a minority interest and purchase option*
  • A leading U.S. pharmaceutical company in connection with product divestitures in the United States and abroad
  • An early-stage U.S. biotech in connection with collaboration programs for a novel delivery system for gene therapies
  • A leading U.S. biotech on the organization of its European commercial activities

* Denotes experience prior to joining Goodwin.

Professional Activities

Mr. Schur is a former trustee, The American Library in Paris, Inc.; former president, Harvard Law School Association of France, and former administrative director, Union Internationale des Avocats.

In The News









J.D., 1978
Harvard Law School
cum laude
A.B., 1975
Harvard College
cum laude



New York
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique